Machelle McDowell, NP
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,719 of the $103,048 with a category attached, or 72.5%. 32 manufacturers reported payments, led by AbbVie at 44.5% of the total. 2025 is the largest year on record at $39,870, 3.7 times the $10,671 reported in 2021. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 724 payments — averaging $142.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Johnson & Johnson$41K
- Janssen Scientific Affairs, LLC$8K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Merck$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- plus $3K from 26 others
Across 6 payments — averaging $198.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$74,71973%
- Travel & lodging$9,7249%
- Food & beverage$18,31318%
- Education$2910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 330 | $45,842 |
| Johnson & Johnson | 86 | $40,980 |
| Janssen Scientific Affairs, LLC | 23 | $8,462 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $1,770 |
| Merck | 11 | $1,308 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 83 | $1,197 |
| Sanofi | 24 | $629 |
| Ardelyx, Inc. | 14 | $391 |
| Gilead | 5 | $319 |
| Pfizer | 23 | $307 |
| Intercept Pharmaceuticals, Inc. | 4 | $233 |
| E.r. Squibb & Sons, L.L.C. | 2 | $191 |
| Aimmune Therapeutics, Inc. | 5 | $187 |
| QOL Medical, LLC | 4 | $157 |
| Evoke Pharma, Inc. | 2 | $148 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Eisai Inc. | 1 | $124 |
| Lilly USA, LLC | 7 | $122 |
| Regeneron Healthcare Solutions, Inc. | 1 | $86 |
| Bristol Myers Squibb | 5 | $75 |
| Janssen Research & Development, LLC | 1 | $54 |
| Nestle Healthcare Nutrition Inc. | 3 | $52 |
| Amgen | 2 | $48 |
| Novo Nordisk | 1 | $46 |
| Organon | 4 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $32 |
| Braintree Laboratories, Inc. | 2 | $30 |
| Celltrion USA Inc. | 2 | $28 |
| AstraZeneca | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Mirum Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,048 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 108 | $2,848,735 |
| Skyrizi On-BodyRisankizumab-Rzaa | 20 | $377,827 |
| XifaxanRifaximin | 113 | $346,240 |
| CreonLipase/Protease/Amylase | 104 | $311,474 |
| ZeposiaOzanimod Hydrochloride | 13 | $116,156 |
| LinzessLinaclotide | 129 | $113,307 |
| RinvoqUpadacitinib | 15 | $85,316 |
| Entyvio PenVedolizumab | 14 | $77,260 |
| Mesalamine | 103 | $40,641 |
| Colestipol Hcl | 86 | $15,602 |
| Dexlansoprazole DrDexlansoprazole | 51 | $14,385 |
| Budesonide ErBudesonide | 13 | $14,188 |
| Mesalamine ErMesalamine | 50 | $12,760 |
| TrulancePlecanatide | 16 | $10,753 |
| Budesonide DrBudesonide | 74 | $8,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $40,980 | $2,848,735108 claims |
| AbbVieCreon, Linzess, Rinvoq | $45,842 | $510,097248 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,197 | $356,993129 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $191 | $116,15613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Tyler
- Jonathan KingTyler$97K
- Kirsten StuberTyler$79K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.